Palleon Pharmaceuticals Announces Successful Defense of European Patent
Palleon Pharmaceuticals, a leading biotech company developing drugs that target glyco-immune checkpoints to treat cancer, today announced that the company, together with the University of Dundee, has successfully defended an opposition to EP1954318, a key European patent owned by the University and exclusively licensed to the company that covers important therapeutic uses of anti-Siglec-9 antibodies. Siglec-9 is a protein found on the surface of various immune cells, including macrophages, dendritic cells, natural killer cells and T cells, that suppresses immune activation. Tumors exploit Siglec-9 to evade the immune response, and blocking this activity with drugs offers a novel strategy to treat cancer. The European patent provides broad patent coverage for Palleon’s Siglec-9 programs.
About Glyco-Immune Checkpoints
Cancer uses multiple pathways to evade the immune system, and glyco-immune checkpoints are a significant and under-appreciated axis of immunosuppression in cancer. Tumors exploit glyco-immune checkpoints, such as Siglec receptors through the alteration of glycans on the surface of their cells, impairing both innate and adaptive immune cells and resulting in a broad, comprehensive suppression of the anti-tumor immune response. Glyco-immune checkpoints had been overlooked relative to other anti-cancer strategies due to the complexity of glycoscience, and, until recently, the lack of scientific tools to demonstrate their function in cancer immune evasion. Palleon has assembled the technologies needed to overcome long-standing technical barriers and make drug development in this field possible.
About Palleon Pharmaceuticals
Palleon Pharmaceuticals is the leading biotechnology company developing drugs that target glyco-immune checkpoints to treat cancer. The company’s proprietary EAGLE, CONVERGENCE and HYDRA platforms integrate technologies and insights from world-renowned scientific leaders in the glyco-immunology field to create a novel approach to treating cancer. By enabling an anti-cancer response from multiple immune cell types, glyco-immune checkpoint inhibition will tackle resistance to existing immuno-oncology agents and make possible a wider range of rational combination therapies to treat cancer. Palleon has several cancer drug discovery programs underway. Beyond oncology, other important areas where glyco-immune checkpoints may play a role include neurodegeneration, inflammation, fibrosis and infectious diseases. The company is advancing its pipeline and development programs with a $47.6 million Series A financing from leading biotech venture investors SR One, Pfizer Ventures, Vertex Ventures HC, Takeda Ventures and AbbVie Ventures. Learn more at www.palleonpharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190206005120/en/